Evidence map›Paper›PMID 26717242›Full record

ArticleJournal of proteome research2016

Unbiased Metabolomic Investigation of Alzheimer's Disease Brain Points to Dysregulation of Mitochondrial Aspartate Metabolism.

Giuseppe Paglia, Matteo Stocchero, Stefano Cacciatore, Steven Lai, Peggi Angel, Mohammad Tauqeer Alam, Markus Keller, Markus Ralser, Giuseppe Astarita

Abstract read
In one paragraph

Article in Journal of proteome research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Metabolic dysregulation in Alzheimer's disease: A brain metabolomics approach.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  12. Article
  13. Review
  14. The role of autoantibodies in Alzheimer's disease: Pathogenetic connections or epiphenomena?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  15. "Advances in biomarker discovery and diagnostics for alzheimer's disease".Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  16. Risk of Alzheimer's disease in Down syndrome: Insights gained by multi-omics.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  17. Article
  18. Global Metabolomics Using LC-MS for Clinical Applications.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giuseppe PagliaCenter for Biomedicine, European Academy of Bolzano/Bozen , Via Galvani 31, 39100 Bolzano, Italy.
Matteo StoccheroS-IN Soluzioni Informatiche S.r.l. , via G. Ferrari 14, 36100 Vicenza, Italy.
Stefano CacciatoreInstitute of Reproductive and Developmental Biology, Imperial College London , London SW7 2AZ, United Kingdom.
Steven LaiWaters Corporation , Milford, Massachusetts 01757, United States.
Peggi AngelProtea Biosciences Group, Incorporated Morgantown, West Virginia 26505, United States.
Mohammad Tauqeer AlamDepartment of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge , 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom.
Markus KellerDepartment of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge , 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom.
Markus RalserDepartment of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge , 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom.
Giuseppe AstaritaWaters Corporation , Milford, Massachusetts 01757, United States.

Funding

European Research Council 260809Medical Research Council FC001134Wellcome Trust 093735Wellcome Trust RG 093735/Z/10/Z
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common cause of adult dementia. Yet the complete set of molecular changes accompanying this inexorable, neurodegenerative disease remains elusive. Here we adopted an unbiased lipidomics and metabolomics approach to surveying frozen frontal cortex samples from clinically characterized AD patients (n = 21) and age-matched controls (n = 19), revealing marked molecular differences between them. Then, by means of metabolomic pathway analysis, we incorporated the novel molecular information into the known biochemical pathways and compared it with the results of a metabolomics meta-analysis of previously published AD research. We found six metabolic pathways of the central metabolism as well as glycerophospholipid metabolism predominantly altered in AD brains. Using targeted metabolomics approaches and MS imaging, we confirmed a marked dysregulation of mitochondrial aspartate metabolism. The altered metabolic pathways were further integrated with clinical data, showing various degrees of correlation with parameters of dementia and AD pathology. Our study highlights specific, altered biochemical pathways in the brains of individuals with AD compared with those of control subjects, emphasizing dysregulation of mitochondrial aspartate metabolism and supporting future venues of investigation.

Indexed as

MetabolomeAgedAged, 80 and overAlzheimer DiseaseAutopsyBrainFemaleHumansMaleMetabolic Networks and PathwaysMetabolomicsMitochondriaPostmortem ChangesSpectrometry, Mass, Electrospray IonizationAlzheimer’s diseaselipidomicslipidsmetabolic pathwaysmetabolomics

Identifiers

PMID26717242
PMCPMC5751881

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.